Natalie Hannan
0000-0001-8446-2250
University of Melbourne
9 papers found
Refreshing results…
Repurposing existing drugs as a therapeutic approach for the prevention of preterm birth
The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health
Silencing of Nrf genes in the human placenta as measured by SDS-PAGE and Western Blotting techniques
A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeks’ gestation in pregnancies destined to deliver small for gestational age infants
Circulating Delta-like homolog 1 (DLK1) at 36 weeks is correlated with birthweight and is of placental origin
Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling
Melatonin enhances antioxidant molecules in the placenta, reduces secretion of soluble fms-like tyrosine kinase 1 (sFLT) from primary trophoblast but does not rescue endothelial dysfunction: An evaluation of its potential to treat preeclampsia
Combining metformin and esomeprazole is additive in reducing sFlt-1 secretion and decreasing endothelial dysfunction – implications for treating preeclampsia
Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction
Missing publications? Search for publications with a matching author name.